Scientists test new pill in hopes of boosting lung cancer treatment
NCT ID NCT04631029
Summary
This early-stage study tested the safety of adding a new oral drug, entinostat, to a standard three-drug regimen for aggressive lung cancer that has spread. The main goal was to find the highest safe dose of this four-drug combination and check for side effects in a very small group of patients. Researchers also wanted to see if adding entinostat could make the standard treatment more effective at controlling the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC MALIGNANT NEOPLASM IN THE BRAIN are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Huntsman Cancer Institute/University of Utah
Salt Lake City, Utah, 84112, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
University of Pittsburgh Cancer Institute (UPCI)
Pittsburgh, Pennsylvania, 15232, United States
-
University of Virginia Cancer Center
Charlottesville, Virginia, 22908, United States
-
University of Wisconsin Carbone Cancer Center
Madison, Wisconsin, 53792, United States
Conditions
Explore the condition pages connected to this study.